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Summary
Atopic Dermatitis affects both children and adults and is a serious health concern in 
many countries. AD is a complex disease with host and environmental factors underlying 
its pathology. Its treatment is multidimensional reflecting the diverse nature of its triggers 
and includes emollients, topical steroids and calcineurin inhibitors among others. Im-
munological dysfunction can be addressed broadly with systemic immunosupressors and 
specifically with monoclonal antibodies. Dupilumab, which targets IL-4 and IL-13 was 
granted approval for treatment of moderate-to-severe AD. Biologics targeting IgE/Th2 
pathways may have its role in patients with overlapping AD and asthma. 
Psychological distress can exacerbate symptoms and is associated with increased severity 
of AD. Environmental triggers, such as, allergens can be addressed in selected cases with 
allergic immunotherapy. 
In this paper, we discuss AD treatment and propose a new step-by-step approach aiming 
at maintaining disease control and improving quality of life.
ty is associated with various inflammatory conditions, including 
asthma and allergic diseases. As such, a fundamental role for 
microorganisms in human health, whether indigenous or envi-
ronmental, is becoming increasingly evident. 
Besides the importance of the environment in the development 
of allergic diseases, an increased familiar predisposition for the 
development of these conditions may exist.  This observation 
led researchers to hypothesize that host genetic factors could 
be involved in the pathogenesis of AD. The description, back 
in 2006, that loss-of-function mutations in the filaggrin (FLG) 
gene were a strong genetic risk factor for AD, became a sig-
nificant breakthrough regarding prognosis and treatment. FLG 
monomers aggregate keratin filaments into tight bundles, re-
sulting in the collapse and flattening of corneocytes that main-
tain both skin barrier integrity and normal stratum corneum 
(SC) lipids. Therefore, mutations in the FLG gene may increase 
skin permeability, predisposing individuals to skin allergen pen-
etration and subsequent infection. These mutations have also 
Introduction
Atopic disorders represent a global health problem with a num-
ber of studies demonstrating an increase in the prevalence of 
asthma, allergic rhinitis (AR) and atopic dermatitis (AD) over 
the last four decades (1). Although current estimates point to 
AD cases leveling off or even decreasing in some countries, such 
as, the United Kingdom and New Zealand, AD remains a seri-
ous health concern in many countries, particularly in the devel-
oping world where the disease is still very much on the rise (2).
The sharp increase in allergic diseases between the early 60s and 
the late 80s is perceived to be a consequence of an intense mi-
gration from rural to urban regions, and from poor, developing 
countries to more affluent, heavily industrialized regions of Eu-
rope, Asia and the Americas. The recent biodiversity hypothesis 
on allergic diseases (3) claims that not only the loss of macrodi-
versity determined by climate change and pollution is associated 
with adverse health effects, but also that the loss of microdiversi-
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been correlated with other atopic disorders such as atopic asth-
ma, although with conflicting and less clear results (4).
Dysfunction of innate and adaptive immune responses are typ-
ical features of AD. Atopic skin exhibits decreased levels of an-
timicrobial peptides and a decreased number of dendritic cells 
when compared with the skin of patients with other inflamma-
tory skin diseases. AD patients have increased risk of developing 
rhinitis and asthma, which suggests a systemic Th2 allergic pre-
disposition in this population (5).
We can consider that host and environmental factors contribute 
to AD pathogenesis and manifestations. The former includes 
genetic background, namely filaggrin gene mutations, innate 
and adaptive immunological dysfunction and psychological as-
pects that interfere with patient’s quality of life. Environmental 
factors include allergens and skin microbiome that can modu-
late expression and severity of AD (figure 1). 
The treatment of patients with AD is therefore multidimension-
al aiming at restoring skin hydration and lipid defects, down-
regulation of allergen-driven skin inflammation, elimination of 
skin pathological inhabitants, and addressing the pruritus that 
perpetuates the vicious cycle of scratching. Recently, new im-
munomodulators have emerged as complementary treatment 
strategies to conventional AD therapies, because these mole-
cules not only diminish symptoms but also address immuno-
logical dysfunction (6).
Our aim is to provide an updated revision on the treatment op-
tions for AD that target both the host (skin barrier, immunolog-
ical deviation) and the environmental factors (allergens and skin 
microbiome) underlying this pathology, with special emphasis 
given to new immunomodulatory drugs.
Host factors
Skin barrier
The first approach to symptoms management is therapy direct-
ed at skin barrier impairment (7). The aim should be to main-
tain skin care, improve skin repair, and keep a healthy skin bar-
rier, in order to suppress the inflammatory response and keep 
itching under control (7). 
Figure 1 - Atopic Dermatitis multicomponents model. AD has a complex pathogenesis with multiple players. Innate and adaptive immune 
dysfunction promote Th2 and Th1 driven inflammation and changes in the normal skin microbiome. The microbiome dysbiosis potentiate 
the irritating action of allergens, air pollutants and smoke. Immunological factors also act on resolution and skin repair leading to chron-
ic lesions characterized by lichenification and fibrosis. The genetic background can, in some subjects, be responsible for the skin barrier 
impairment leading to a more severe disease. Intensity and extension of lesions are the main determinants of symptoms (pruritus, pain, skin 
discomfort). Psychological factors such as anxiety can potentiate symptoms and symptoms can lead to psychological distress such as depression 
and quality of life impairment. Adapted from Anderson (58).
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Emollients are the first step in the treatment regimen of AD 
because they promote skin care and repair, restore epidermal 
function, suppress inflammation and maintain itch control (8, 
9). Emollients are topical preparations and can be delivered via a 
variety of formulations, including creams, ointments, oils, gels, 
and lotions. Emollients are normally used in a liberal way, aim-
ing at maintaining minimal xerosis (8). Their use may be espe-
cially relevant in patients with FLG deficiency since this leads to 
defects in the formation of the stratum corneum (SC), decreases 
the ability to maintain its hydration, and induces a parallel ele-
vation in pH, lipid bilayer disorganization, percutaneous aller-
gen exposure and xerosis (10). 
Emollients are designed to maintain the skin’s softness and hy-
dration and can be occlusive, humetant or lipidic. Occlusive 
emollients maintain the external hydrophobic layer of the skin 
surface reducing transepidermal water loss levels (TEWL); hu-
metant emollients have hydrophilic hydroxil groups and are 
capable of retaining water within the skin, either by attracting 
water from the dermis or from the external environment (when 
relative ambient humidity is greater than 70%); lipidic emol-
lients, such as ceramides, replenish the lipid component of the 
SC, which is decreased in AD, and by doing so, they improve 
transepidermal water content in children (11). 
Emollients have numerous beneficial effects for AD patients in-
cluding decreasing the number and increasing the time to flares 
and reducing the amount of topical corticosteroids needed (12) 
Randomized controlled trials have demonstrated the benefits of 
long-term use of emollients in xerosis control, which translates 
into better quality of life (QoL) of patients (13). When the reg-
ular use of emollients fails to achieve satisfactory skin care and 
reduced symptoms, other topical therapies are required(8).
Topical corticosteroids (TCS) are the core of anti-inflammato-
ry therapy, being used in children and in adult patients when 
the lesions fail to respond to good skin care and regular use of 
moisturizers alone (9). They act on a multitude of immune cell 
populations, namely T lymphocytes, monocytes, macrophages, 
and dendritic cells, decreasing the release of pro-inflammatory 
cytokines (8). TCS also reduce Staphylococcus aureus bacterial 
load, likely via decreasing the inflammatory cytokines that in-
hibit antimicrobial peptide production.
TCS are utilized for active inflammatory flares of disease and for 
prevention of relapses, decreasing both acute and chronic signs 
of AD, as well as pruritus (8). A meta-analysis of randomized 
controlled trials has advocated a proactive approach of main-
tenance therapy for those patients with repeated outbreaks at 
the same body sites. When used once to twice weekly at these 
particular body locations, TCS reduced the rates of relapse and 
increased time to first flare relative to the use of moisturizers 
only. TCS are grouped into classes according to anti-inflam-
matory potency, and selection of steroid should be guided by 
location, extent and acute or chronic nature of skin lesions, pa-
tients’ age, and disease severity. Low-potency TCS are indicated 
for mild disease, flexural and facial skin lesions, young children 
and pregnant women. High potency TCS are preferred for older 
patients, lichenified and chronic prurigo-like lesions and palms 
(14).
It has been shown that TCS have a greater absorption rate and 
systemic uptake in patients with clinically severe disease, when 
compared to patients with mild or moderate disease, suggest-
ing caution in their use in more advanced stages of the disease 
and in infants (15). The incidence of reported side effects from 
TCS use is low; however, most studies fail to follow patients 
long-term for potential complications. Cutaneous side effects 
include purpura, telangiectasias, striae, focal hypertrichosis, and 
acneiform or rosacea-like eruptions. Of greatest concern is skin 
atrophy, which can be induced by any TCS, though higher po-
tency agents, occlusion, use on thinner skin, and older patient 
age increase this risk. Continuous application of TCS for long 
periods of time should be avoided, to limit the occurrence of 
negative changes. Proactive, once to twice weekly application 
of mid-potency TCS for up to 40 weeks has not demonstrated 
these adverse events in clinical trials (8).
 Topical calcineurin inhibitors (TCIs) are a class of anti-inflam-
matory topical therapy that inhibits calcineurin-dependent 
T-cell activation, decreasing the production of inflammatory 
cytokines (8). Pimecrolimus and tacrolimus are approved in the 
EU from 2 years of age and above. TCIs can be used in patients 
who fail to respond to other topical therapeutics such as TCS or 
as a complementary approach (8, 9). The long-term use of TCIs 
is supported by robust data, documenting safety and efficacy, 
while data supporting long-term TCS use are limited to low- 
to mid-potency products (8). Despite this, a meta-analysis by 
Broeders et al demonstrated that TCIs and TCS led to a similar 
percentage of patients presenting improvements in dermatitis 
and of treatment success rates both in children and adults (16). 
Pruritus in AD is multifactorial depending on other mediators 
than histamine like nerve growth factor, substance P, protease, 
and cytokines/chemokines (thymic stromal lymphopoietin 
(TSLP), IL-2, IL-4, IL-13, and IL-31) (17) explaining with 
anti-histamines have demonstrated little utility despite their 
frequent use topical anti-histamines, because of risk of sensitiza-
tion, are contra-indicated (8). Oral sedative H1 antihistamines 
are not recommended because of the risk of adverse reactions 
such as increased somnolence or restlessness, confusion, etc. A 
summary of the main conclusions regarding skin barrier is pre-
sented on box 1.
Immune deviation
Systemic immunomodulatory therapy is reserved for patients 
with poor response to non-pharmacological or topical treatment, 
with persistence of symptoms and impairment of QoL (18). All 
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immunomodulatory agents should be adjusted to the minimal 
effective dose once response is achieved, and topical treatments 
should also be maintained in order to allow the lowest dose and 
duration of systemic agents. Both non-specific and specific im-
mune systemic therapies are available for these patients.
Non-biologic systemic drugs used for adult AD include cyc-
losporine, corticosteroids, azathioprine, methotrexate (MTX) 
and mycophenolate mofetil (MMF), which exert their immu-
nosuppressive effects by reducing inflammatory cell numbers 
and pro-inflammatory cytokines expression (19). Phototherapy 
is also frequently used as a second-line treatment for moder-
ate-to-severe AD in adults (20).
Cyclosporine is an immunomodulatory drug that inhibits inter-
leukin IL-2 and T-lymphocytes. According to Consensus-based 
European guidelines for treatment of atopic dermatitis it is the 
first choice for systemic treatment of severe adult AD patients 
who are unresponsive to topical therapy and require systemic 
immunosuppressive treatment (21). An initial daily dose of 2.5–
3.5 mg ⁄ kg ⁄ day and a maximal daily dose of 5 mg ⁄ kg ⁄ day, di-
vided upon two single doses, is recommended. A dose reduction 
of 0.5–1.0 mg⁄ kg ⁄ day every 2 weeks is desirable as indicated 
by clinical efficacy. It can be used as a continuous therapy, but 
a maximum duration of 1–2 years has been suggested to avoid 
adverse events such as nephrotoxicity, hypertension, tremors, 
headaches, paresthesia, nausea, diarrhea, myalgias, electrolyte 
imbalance, hyperlipidemia, hypertrichosis and gingival hyper-
plasia. Patients receiving cyclosporine should be monitored for 
blood pressure and renal parameters, as cyclosporine is known 
to induce structural and organic kidney damage. Nephrotoxic 
effects are more likely to occur if the daily dose exceeds 5 mg⁄ 
kg body weight, serum creatinin values are elevated or elderly 
patients are treated (22). Cyclosporine may be used ‘off label’ in 
children and adolescent patients showing a refractory or severe 
course of disease (23).
Systemic corticosteroids decrease the transcription of several 
mediators involved in the pathogenesis of AD, including cy-
tokines, chemokines and adhesion molecules, by binding to 
regulatory elements on many genes, thus leading to resolution 
of inflammation (19, 24). Despite rapidly improving disease ac-
tivity, systemic corticosteroids (oral or parenteral) have a largely 
unfavorable risk/benefit ratio for adult AD treatment (19, 24) 
and long-term use is not recommended (18, 19, 24). Also, a re-
bound flare and increased disease severity is frequently seen after 
discontinuation of systemic steroids. Short-term (up to 1 week) 
treatment may be an option to treat acute flares in exceptional 
and severe cases of AD (19, 21, 24). 
Azathioprine is a purine analog that inhibits DNA production 
and reduces leukocyte proliferation thus decreasing inflamma-
tion (18). It is used off-label for the treatment of severe AD in 
adults, in particular in the UK and USA (18, 19, 24). It may be 
used off-label when cyclosporine is either not effective or con-
traindicated (21). Although several studies have demonstrated 
QoL improvement and symptomatic control with azathioprine 
usage in AD(18), data on efficacy and safety are still sparse. Ad-
verse events of azathioprine include gastrointestinal disturbanc-
es, liver dysfunction and leukopenia (19, 24).
Methotrexate (MTX) is an antimetabolite that regulates the im-
mune system and inflammatory processes, by interfering with 
folic acid metabolism through blocking of RNA, DNA and 
purines’ synthesis (18). Several studies suggested that MTX is 
well-tolerated and effective in the treatment of moderate-to-se-
vere forms of AD(19) even if its use is off-label.  Nonetheless, 
liver and bone marrow toxicity have to be monitored before and 
during MTX therapy. The adverse events most commonly caus-
ing discontinuation of MTX treatment include nausea, fatigue, 
hepatotoxicity, hematological abnormalities, pulmonary toxici-
ty and drug interaction. Folic acid supplementation is recom-
mended during treatment with MTX to reduce the likelihood 
of hematologic and gastrointestinal toxicity.
Mycophenolate mofetil (MMF) is also an antimetabolite that 
blocks the purine biosynthesis pathway selectively inhibiting B- 
and T-cell proliferation. Several case reports and small studies 
showed its efficacy when used off-label in adult patients with 
AD who were unresponsive to cyclosporine therapy (19, 21). 
The main adverse events reported during MMF therapy were 
nausea, fatigue, flu-like syndrome and liver enzyme alteration. 
Phototherapy with artificial UV radiation is frequently used as a 
second-line treatment for moderate-to-severe AD in adults (20). 
Narrowband UVB is preferred over broadband UVB for AD 
treatment if available (9). UV irradiation is able to modulate 
the immune response of AD patients through upregulation of 
FoxP3-positive regulatory T cells, whose number is directly cor-
related with the degree of AD severity score. Phototherapy can 
be used as short- and/or long-term treatment. TCS and emol-
lients can be associated with phototherapy to reduce flare-ups, 
whereas TCIs should be avoided to limit the risk of carcinogen-
esis (9, 20). Phototherapy must be performed conscientiously, 
especially in children, and must take into account the patient’s 
features and overall condition (20).
Severe refractory AD patients that fail to improve with systemic 
immunosuppressive therapy, or those who experienced import-
Box 1  Summary of the main conclusions regarding skin 
barrier.
● The use of emollients prevents exacerbations
● Flares should be treated with topical corticosteroids
● Topical calcineurin inhibitors should be used as a 
complementary approach, especially in sensitive skin 
areas 
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ant side effects, may benefit from biologic therapy. Biological 
therapies for AD include several monoclonal antibodies, of 
which omalizumab and dupilumab are the best studied. Cur-
rently, dupilumab is the only biological therapy approved for 
treatment of moderate-to-severe AD by the Food and Drug Ad-
ministration (FDA) and European Medicines Agency (EMA).
Omalizumab is a humanized monoclonal antibody that binds 
to the high-affinity IgE receptor, preventing IgE from binding 
to the surface of several cell types including mast cells, baso-
phils, dendritic cells and eosinophils, and so blocking mast-
cell degranulation and decreasing the release of cytokines and 
recruitment of other inflammatory cells (25). Treatment with 
Omalizumab is currently indicated in adults, adolescents and 
children (> 6 years of age) with severe persistent allergic asthma 
and in refractory  chronic spontaneous urticaria (26). Although 
data from case series and case reports documented clinical bene-
fit of AD, some studies showed no improvement of disease with 
Omalizumab both in adults and children (27, 28). Nevertheless, 
a recent randomized clinical trial found that Omalizumab sig-
nificantly reduced atopic dermatitis severity and improved qual-
ity of life in a pediatric population (4-19 years old) with atopy 
and severe AD despite highly elevated total IgE levels at base-
line  (29). Due to AD heterogeneity, it seems that some patients 
are most likely to respond to anti-IgE therapy: lack of filaggrin 
mutations and lower elevations of total serum IgE are factors 
associated with a likely favorable response to Omalizumab (30, 
31). Based on case reports and case series, targeting IgE seems to 
be an option in patients who have overlapping allergic diseases 
such as asthma (32). However at this time, available scientific 
evidence does not support its use for the treatment of AD (21) 
and larger RCTs are needed. 
Dupilumab is a fully human monoclonal antibody that targets 
IL-4Rα and inhibits signaling of IL-4 and IL-13, both of which 
are key Th2 cytokines that play an important role in AD.(33) 
The data supporting its efficacy and safety came from two 
randomized, placebo-controlled, phase 3 trials, SOLO 1 and 
SOLO 2, involving 671 and 708 adult patients, respectively, > 
18 years of age with moderate-to-severe AD (34). Dupilumab 
has a favorable safety profile with no dose-limiting toxicity and 
few adverse events, including nasopharyngitis, upper respiratory 
tract infections, conjunctivitis, headache, injection-site reaction 
and back pain (33, 34). Dupilumab, is indicated for the treat-
ment of moderate-to-severe AD in adolescent and adult patients 
who are candidates for systemic therapy (35, 36). European 
Guidelines for the treatment of AD recommend dupilumab as 
a disease-modifying drug for patients with moderate-to-severe 
AD, combined with daily emollients (21). Dupilumab has also 
recently been approved for treatment of severe asthma (37) and 
severe chronic rhinosinusitis with nasal polyps (38). Box 2 sum-
marizes the main conclusions regarding non-specific and specif-
ic immune systemic therapies.
Psychotherapy
AD is associated with other allergic conditions and psychosocial 
disorders. Specifically, the prevalence of depression, anxiety and 
other psychiatric disorders are higher in AD patients than in 
the general population, due to social isolation, sleep deprivation 
and persistency of symptoms (39).
Psychotherapy through cognitive behavioral stress management 
has a positive impact in the burden of disease, namely on the 
improvement of endocrine and psychological stress responses 
(39). Some studies demonstrated an effective decrease of anxi-
ety in adults, as well as in children (39). Moreover, psychological 
interventions are associated with better managing of symptoms 
and a decrease in itching intensity (39). A summary of the main 
conclusions regarding psychotherapy is presented on box 3.
Environmental factors
Allergens
Historically, the relationship between exposure to allergens, 
specifically inhaled allergens (horse dander, ragweed pollen, 
timothy grass) and AD was demonstrated in 1918 (40). Cur-
rently, it is known that in some phenotypes of AD there is an 
immune response to allergens, mediated by IgE and T cells (41). 
The skin barrier function and innate immunity are involved 
in this pathology due to the properties of some allergens (41) 
that facilitate barrier disruption and cutaneous sensitization. It 
has been shown that exogenous protease activity of house dust 
Box 2   Main conclusions regarding non-specific and 
specific immune systemic therapies.
Box 3  Main conclusions regarding psychotherapy.
● Systemic therapy should only be used if topical 
therapy fails
● Cyclosporine is the first-line option for patients who 
require systemic immunosuppressive treatment
● Systemic corticosteroids should only be used in 
exacerbations and for short periods of time
● Dupilumab, which targets IL-4 and IL-13 is approved 
for treatment of moderate-to-severe AD. 
● Biologics targeting IgE/Th2 pathways may have its 
role in patients with overlapping AD and asthma. 
● Psychological distress can be an exacerbating factor of 
AD
● Psychological interventions may benefit AD patients
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mite, insects, fungi, and pollen disrupts inter-corneocyte con-
nections and Der f 1 allergen disrupts epidermal tight junctions 
and induces inflammatory mediator release, such as IL-6, IL-8 
and GM-CSF, by keratinocytes (42). Itching and delayed skin 
barrier recovery from mite and cockroach allergen exposure is 
mediated by activation of protease-activated receptor-2 (PAR-
2) expressed by keratinocytes and dermal unmyelinated nerve 
fibers (41). It is also known that PAR-2 binding capacity is en-
hanced by exposure to UV, with PAR-2 expression increasing 
in the superficial epidermis after UV exposure. Therefore, the 
proteolytic properties of allergens, together with UV exposure, 
may be a possible link behind the seasonal trend of AD. 
Despite the biological plausibility of avoidance measures, studies 
conducted so far provide conflicting results regarding reduced 
indoor contact with mite allergens (43). A recent Cochrane 
Review concluded that very low quality evidence was current-
ly available regarding house dust mite reduction or avoidance 
measures for treating eczema (44). Several possible reasons for 
the failure of indoor avoidance measures exist: the effectiveness 
of avoidance measures is difficult to ascertain (e.g., are vacuum 
steam cleaning and air-filters effective?); adherence to avoid-
ance measures is not measurable nor is the exposure to allergens 
outside home; and finally long-term established disease is less 
likely to respond to avoidance measures (43). When addressing 
specific immunotherapy (SIT) with aeroallergens in AD, there 
is conflicting evidence, with more recent literature being more 
in favor of it (45). SIT may have positive effects in selected, 
highly sensitized patients with AD and the best evidence so far 
is available for SIT with house dust mite allergens (45). There is 
no contraindication for performing SIT in patients with respi-
ratory allergic diseases (allergic rhinoconjunctivitis, mild allergic 
bronchial asthma) and concomitant AD (22).
Regarding food allergens, the diagnosis of eczematous reactions 
to food requires a careful diagnostic procedure, taking into ac-
count the patient’s history and sensitization patterns. The clinical 
relevance of sensitization often has to be proven by an oral food 
challenge, with the rating of the skin condition being performed 
by validated scores after 24h and the evaluation of the eczem-
atous reaction at a later point in time (46). Moreover, a large 
recent study investigating food allergy and AD exacerbations 
concluded that children with AD exacerbations in the absence of 
other allergic symptoms are unlikely to be food allergic (46). Box 
4 summarizes the main conclusions regarding allergens.
Skin microbiome in AD patients
Metagenomic studies have revealed that diverse and complex mi-
crobial ecosystems inhabit the skin and are collectively known as 
the skin microbiome. The skin microbiome is composed mainly 
of members of the same four phyla that comprise the gut micro-
biome, although with dissimilar relative abundances. In all indi-
viduals, Propionibacterium species dominates in sebaceous areas 
such as the forehead, retroauricular crease, and back, whereas 
Staphylococcus and Corynebacterium species dominate in moist 
areas, such as the axillae. Abundant Gram-negative organisms, 
previously thought to colonize the skin rarely as gastrointestinal 
contaminants, were found in the microbiomes of dry skin habi-
tats, such as the forearm or leg (47). 
Interest in the relationship between AD and metagenomics is 
increasing. Studies show that S. aureus increased from 35% to 
90% of the microbiome during flare-ups, with concomitant in-
crease of S. epidermidis (48). It is still unclear if S. aureus and 
S. epidermidis mutually enhance each other’s colonization or if 
S. epidermidis increase reflects an antagonistic response to an 
increasing S. aureus population. S. aureus produce superantigens 
(S. enterotoxin A, B and C, and toxic shock syndrome toxin-1), 
which are important effectors in AD. They cause S. aureus-spe-
cific IgE production and this correlates with disease severity. 
Superantigens also cause nonspecific IgE production, activate 
T cells, B cells and macrophages, and stimulate their prolifera-
tion (49). Superantigens also induce chemokines such as CCL1 
and CCL18, which bind to CLA-positive T cells in peripheral 
blood and thus are likely to play a role in T cell homing to the 
skin. The superantigens seem to reduce the immunosuppressive 
activity of certain immunosuppressive regulatory T cells, which 
may, in turn, increase inflammatory T cell activation (49). They 
are also known to induce corticosteroid resistance, thus hamper-
ing the treatment of atopic diseases. 
Although infected AD exacerbations require specific treatment 
of microorganisms in combination with AD treatment, no ev-
idence supports the assumption that antimicrobial treatment 
of colonized skin will benefit patients in the long-term (49). 
Moreover, combining topical antibiotic agents with corticoste-
roid treatment has led to no further decrease in S. aureus col-
onization compared with corticosteroid alone (50). Therefore, 
antibiotic treatment should be used with caution. 
With the development of nanotechnology, intelligent or func-
tional textiles with antiseptic properties are available. Such 
Box 4  Main conclusions regarding allergens.
● An immunological rationale for aeroallergen eviction 
exists although scientific evidence for this measure to 
be undertaken lacks
● Physicians should be cautious when considering food 
allergen eviction and only propose it after evidence of 
clinical relevance
● Specific allergen immunotherapy to house dust mites 
has shown efficacy in some studies
● Exposure to irritant environmental factors such as 
tobacco should be avoided
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textiles have been used as adjuvants and antiseptic dressings 
in burns and wound healing with promising results. In immu-
nologically mediated skin diseases, and AD in particular, the 
focus has been to improve itch, severity of lesions, and skin 
colonization by S. aureus. Most of the studies of functional 
textiles in AD have investigated the use of specially treated 
long-sleeved shirts and pants in close contact with the skin. 
Cotton textiles can be functionalized with antiseptic silver salts 
or borage oil, which supplies unsaturated fatty acids to the skin 
barrier (51). Silk coated with specific antimicrobial chemical 
compounds and smooth ethylene vinyl alcohol (EVOH) fibers 
are also used to diminish physical stimuli applied to the skin 
(51). A systematic review provided a weak recommendation for 
the use of these textiles in AD based on low quality of evidence 
supporting the effectiveness of these functional textiles in al-
leviating symptoms and reducing disease severity (51). Nev-
ertheless, recent studies with new biocompounds showed that 
chitosan-coated textiles may impact disease severity, by modu-
lating the staphylococcal profile in the skin, and have a poten-
tial effect on QoL (52). However, further studies are needed to 
confirm these data, to identify which mechanisms are targeted, 
and to determine how functional textiles contribute to symp-
tom improvement. 
Besides pathogenic bacteria, other causes of infections in AD 
patients are virus and fungi. Herpes simplex virus (HSV) can 
lead to the disseminated HSV infection eczema herpeticatum, 
probably the most feared complication of AD (53). In addi-
tion, Malassezia yeast species colonize the skin of 90% of AD 
patients compared with 35% of healthy controls, especially the 
sebaceous areas of the face, scalp and upper body. Species asso-
ciated with AD include Malassezia globosa, sympodialis, restricta, 
and furfur (54). Their role in AD exacerbations is controversial 
despite the fact that specific IgE antibodies towards Malassezia 
species can be found in AD patients but not in healthy controls 
(55). No evidence supports that antifungal treatments reduc-
ing Malassezia colonization would relieve AD in the long-term, 
although treatment periods with an antifungal agent have had 
some effect, especially on eczema in the sebaceous areas. Box 
5 summarizes the main conclusions concerning the skin mi-
crobiome.
Treatment algorithm proposal
Considering all the different treatment approaches in AD, we 
aimed to develop a rationale and step by step approach accord-
ing to its degree of severity and control– figures 2 and 3.
Assessing disease severity 
Regarding disease severity, it must be determined by evaluating 
both objective signs (physician assessments of disease severi-
ty) and subjective symptoms (patient-reported symptoms and 
Quality of life outcomes). One of the most commonly used 
tools for assessing AD severity is SCORing Atopic Dermatitis 
(SCORAD); SCORAD attributes around 60% of the total score 
to the intensity of lesions, 20% to spread and 20% to subjective 
signs scored by the patient(56). A SCORAD > 50 is regarded as 
severe, while SCORAD scores < 25 are considered mild. Con-
sidering Quality of life, Dermatology Quality of life question-
naires (DLQI) and the Infants’ Dermatology Quality of Life 
Index (IDQOL) are the QoL instruments most commonly used 
in AD, taking into account the different disease domains, in par-
ticular signs and symptoms; sleep quality; work performance and 
social and emotional well-being; to quantify the different aspects 
of the individual burden of AD in a real-world setting.
Assessing control
In contrast with other allergic diseases such as asthma, no clear 
and globally accepted definition of control exists for AD. Lan-
gan et al (57) recently described a totally controlled week as one 
in which symptoms are well controlled every day. A well-con-
trolled week was one in which increased symptoms have oc-
curred or treatment has been applied for a period of 2 days or 
less and symptoms are controlled most of the time. In every 
clinical evaluation AD control should be addressed evaluating 
daytime and nocturnal symptoms, limitation of activities, need 
of rescue treatment and occurrence of flares (figure 2).
AD treatment should be based on a personalized cycle of as-
sessment, adjustment of treatment, and review of the response. 
For each patient in addition to treatment of modifiable risk 
factors such as stress, controller medication can be adjusted up 
and down in a stepwise approach to achieve good symptom 
control and minimize risk of future exacerbations. The num-
ber of well controlled weeks will give the clinician a measure 
of disease control in a determined period of time. Once AD 
control has been maintained for 2-3 months treatment may be 
stepped down in order to find the patient minimum effective 
treatment. If a patient has persisting uncontrolled symptoms 
and/or exacerbations despite 2-3 months of controller treat-
ment, the clinician should assess and correct some problems 
before considering any step up in treatment: poor adherence, 
Box 5   Main conclusions concerning the skin 
microbiome.
● AD is associated with loss of diversity of the skin 
microbiome
● Staphylococcus aureus colonization is associated with 
increased disease severity
● When overt clinical infection, antibiotic treatment 
should be considered
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Figure 2 – Algorithm proposal for Atopic Dermatitis management. Consider stepping up treatment, with or without overlapping, to attain 
total control. Adapted from Global Initiative for asthma available at https://ginasthma.org.
persistent exposure to home/work agents such as allergens, co-
morbidities that may contribute to poor quality of life and in-
correct diagnosis.
Key points regarding stepwise approach of AD treatment:
Mild Atopic dermatitis
• When used on a daily basis, moisturizers with non-aqueous 
emollients, occlusive agents and humectants improve barrier 
function; reduce AD signs and symptoms, and the need for 
topical corticosteroids.
• Topical corticosteroids remain the first line treatment, reduc-
ing disease recurrence when used intermittently in patients 
with established disease.
Stepping up if AD remains uncontrolled despite good adherence:
• for patients with persistent symptoms and /or flares consider 
proactive therapy with topical tacrolimus or glucocorticoste-
roids class III;
• if disease control cannot be achieved with topical measures, 
when topical therapies fail or become unacceptable or im-
practical, systemic therapy is indicated.
Stepping down to find the minimum effective dose:
• consider step-down once AD control has been achieved and 
maintained for about 3 months, to find the lowest treatment 
that controls both symptoms and exacerbations;
• provide the patient with a written AD action plan, monitor 
closely and schedule a follow up visit in a 3-4 month period.
For all patients with AD:
• encourage adherence to emollients use, even when symptoms 
are infrequent;
• provide training in AD self-management to control symp-
toms and minimize risk of exacerbations.
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Conclusions
AD is a complex disease with host and environmental factors un-
derlying its pathology. There are several different treatment ap-
proaches in AD, such as emollients, topical steroids, calcineurin 
inhibitors, systemic general immunosupressors and monoclonal 
antibodies. Dupilumab is the only biologic currently approved 
for adolescents and adult patients with moderate-to-severe AD. 
Biologics targeting IgE/Th2 pathways may have its role in pa-
tients with overlapping AD and asthma. 
We propose a new step by step approach aiming at maintaining 
disease control and improving quality of life.
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